<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial systemic therapy in advanced cutaneous squamous cell carcinoma not amenable to locoregional therapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial systemic therapy in advanced cutaneous squamous cell carcinoma not amenable to locoregional therapy</h1>
<div class="graphic"><div class="figure"><div class="ttl">Initial systemic therapy in advanced cutaneous squamous cell carcinoma not amenable to locoregional therapy</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">The decision to start systemic therapy and the selection of agent(s) depend on availability and access to treatment, disease-related symptoms, and patient performance status and comorbidities. Given the rarity of this disease, clinical trials are encouraged at any time during treatment, where available. Refer to UpToDate content on systemic treatment of advanced cutaneous SCC.</div><div class="graphic_footnotes"><p>SCC: squamous cell carcinoma.</p>
<p>* We do not offer immunotherapy agents to patients with SCC secondary to immunosuppression related to allogeneic organ transplantation. For other patients, multiple clinical factors influence eligibility for immunotherapy including patient performance status, medical comorbidities, history of autoimmune disease, and use of immunosuppressive therapy or glucocorticoids. Refer to UpToDate content on systemic treatment of metastatic melanoma with molecular alterations.</p>
<p>¶ Any of these agents are reasonable, as they have not been directly compared in clinical trials, and all are effective and less toxic than other available systemic agents.</p>
Δ Response rates are limited for systemic chemotherapy. Alternative options include cisplatin either as monotherapy or in combination with other agents (eg, fluorouracil with or without bleomycin; anthracyclines); single-agent carboplatin; topical fluorouracil, capecitabine, and methotrexate.</div><div id="graphicVersion">Graphic 131716 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
